R&D pipeline progressing well
20/11/20 -"Better than expected performance of Tepezza and the upcoming launch of Amivantamab should bolster Genmab’s top line in the near term. Moreover, encouraging clinical data for pipeline assets, ..."
Pages
44
Language
English
Published on
20/11/20
You may also be interested by these reports :
12/02/26
Ipsen concluded 2025 with sales and profitability exceeding expectations, driven by growth across all therapeutic areas. The 2026 guidance surpassed ...
12/02/26
Since the beginning of 2025, and even after the new CEO (Maziar Mike Doustdar) was appointed in August 2025, Novo has downgraded growth expectations ...
10/02/26
Even though Q4 25 operating profitability missed the street’s expectations, Astra met its full-year CER guidance. The Q4 performance was largely ...
06/02/26
Q4 ‘25 results exceeded consensus, as Lundbeck met its 2025 guidance. Strong growth for depression treatment Rexulti and migraine medicine Vyepti ...